Revvity EBITDA 2012-2026 | RVTY
Revvity annual and quarterly EBITDA history from 2012 to 2026. EBITDA can be defined as earnings before interest, taxes, depreciation and amortization.
- Revvity EBITDA for the quarter ending June 30, 2026 was $0.193B, a 1.08% decline year-over-year.
- Revvity EBITDA for the twelve months ending June 30, 2026 was $0.776B, a 2.75% decline year-over-year.
- Revvity 2025 annual EBITDA was $0.767B, a 1.81% decline from 2024.
- Revvity 2024 annual EBITDA was $0.781B, a 5.54% increase from 2023.
- Revvity 2023 annual EBITDA was $0.74B, a 39.48% decline from 2022.
|
Revvity Annual EBITDA (Millions of US $) |
|
|---|---|
| 2025 | $767 |
| 2024 | $781 |
| 2023 | $740 |
| 2022 | $1,222 |
| 2021 | $1,610 |
| 2020 | $1,074 |
| 2019 | $601 |
| 2018 | $527 |
| 2017 | $409 |
| 2016 | $397 |
| 2015 | $365 |
| 2014 | $279 |
| 2013 | $361 |
| 2012 | $237 |
| 2011 | $212 |
|
Revvity Quarterly EBITDA (Millions of US $) |
|
|---|---|
| 2026-06-30 | $193 |
| 2026-03-31 | $182 |
| 2025-12-31 | $216 |
| 2025-09-30 | $185 |
| 2025-06-30 | $195 |
| 2025-03-31 | $171 |
| 2024-12-31 | $225 |
| 2024-09-30 | $207 |
| 2024-06-30 | $195 |
| 2024-03-31 | $154 |
| 2023-12-31 | $184 |
| 2023-09-30 | $179 |
| 2023-06-30 | $189 |
| 2023-03-31 | $187 |
| 2022-12-31 | $243 |
| 2022-09-30 | $229 |
| 2022-06-30 | $360 |
| 2022-03-31 | $390 |
| 2021-12-31 | $399 |
| 2021-09-30 | $258 |
| 2021-06-30 | $411 |
| 2021-03-31 | $542 |
| 2020-12-31 | $419 |
| 2020-09-30 | $312 |
| 2020-06-30 | $236 |
| 2020-03-31 | $107 |
| 2019-12-31 | $205 |
| 2019-09-30 | $141 |
| 2019-06-30 | $151 |
| 2019-03-31 | $105 |
| 2018-12-31 | $165 |
| 2018-09-30 | $126 |
| 2018-06-30 | $142 |
| 2018-03-31 | $94 |
| 2017-12-31 | $126 |
| 2017-09-30 | $105 |
| 2017-06-30 | $102 |
| 2017-03-31 | $77 |
| 2016-12-31 | $118 |
| 2016-09-30 | $101 |
| 2016-06-30 | $92 |
| 2016-03-31 | $86 |
| 2015-12-31 | $72 |
| 2015-09-30 | $104 |
| 2015-06-30 | $98 |
| 2015-03-31 | $91 |
| 2014-12-31 | $11 |
| 2014-09-30 | $88 |
| 2014-06-30 | $99 |
| 2014-03-31 | $81 |
| 2013-12-31 | $129 |
| 2013-09-30 | $92 |
| 2013-06-30 | $73 |
| 2013-03-31 | $67 |
| 2012-12-31 | $5 |
| 2012-09-30 | $75 |
| 2012-06-30 | $83 |
| 2012-03-31 | $74 |
| 2011-12-31 | $14 |
| 2011-09-30 | $65 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $14.338B | $2.856B |
| Revvity Inc. provides products, services and solutions to the diagnostics, life sciences and applied services markets worldwide. Its operating segment includes Discovery & Analytical Solutions and Diagnostics. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection and imaging technologies. Revvity Inc., formerly known as PerkinElmer Inc., is based in Waltham, Massachusetts. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Danaher (DHR) | United States | $142.882B | 25.03 |
| CVS Health (CVS) | United States | $122.206B | 12.19 |
| HCA Healthcare (HCA) | United States | $92.119B | 14.32 |
| Elevance Health (ELV) | United States | $92.005B | 14.44 |
| Cencora (COR) | United States | $62.254B | 19.02 |
| Natera (NTRA) | United States | $49.267B | 0.00 |
| Labcorp Holdings (LH) | United States | $25.572B | 18.03 |
| Viatris (VTRS) | United States | $19.136B | 6.61 |
| Medpace Holdings (MEDP) | United States | $16.619B | 34.90 |
| DiDi Global (DIDIY) | China | $16.275B | 178.51 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $16.114B | 0.00 |
| Solventum (SOLV) | United States | $15.290B | 12.65 |
| Charles River Laboratories (CRL) | United States | $13.038B | 27.59 |
| ICON (ICLR) | Ireland | $12.935B | 17.58 |
| BrightSpring Health Services (BTSG) | United States | $11.931B | 41.02 |
| Avantor (AVTR) | United States | $10.254B | 18.49 |
| BioMerieux (BMXMF) | France | $10.192B | 0.00 |
| HealthEquity (HQY) | United States | $7.944B | 25.89 |
| Caris Life Sciences,�Inc (CAI) | United States | $7.362B | 72.36 |
| PACS (PACS) | United States | $7.051B | 23.70 |
| Sonic Healthcare (SKHHY) | Australia | $6.687B | 0.00 |
| GETINGE (GNGBY) | Sweden | $6.654B | 18.79 |
| CochLear (CHEOY) | Australia | $6.355B | 0.00 |
| Bausch + Lomb (BLCO) | Canada | $6.282B | 23.76 |
| MiniMed (MMED) | United States | $6.181B | 0.00 |
| Sotera Health (SHC) | United States | $5.285B | 21.79 |
| Concentras Parent (CON) | United States | $4.566B | 22.52 |
| Organon (OGN) | United States | $3.585B | 4.55 |
| CareDx (CDNA) | United States | $2.709B | 308.06 |
| Alignment Healthcare (ALHC) | United States | $2.684B | 68.11 |
| GeneDx Holdings (WGS) | United States | $2.676B | 249.28 |
| Amplifon S.p.A (AMFPF) | Italy | $2.466B | 12.74 |
| Pediatrix Medical (MD) | United States | $2.187B | 12.81 |
| Establishment Labs Holdings (ESTA) | United States | $2.143B | 0.00 |
| Progyny (PGNY) | United States | $2.137B | 30.27 |
| COMPASS Pathways (CMPS) | United Kingdom | $2.013B | 0.00 |
| Sonida Senior Living (SNDA) | United States | $1.914B | 0.00 |
| Surgery Partners (SGRY) | United States | $1.838B | 70.20 |
| Bora Pharmaceuticals, - (BORAY) | Taiwan | $1.695B | 10.18 |
| Freenome (FRNM) | United States | $1.607B | 0.00 |
| Ardent Health (ARDT) | United States | $1.552B | 8.87 |
| Agilon Health (AGL) | United States | $1.551B | 0.00 |
| Nutex Health (NUTX) | United States | $1.486B | 8.52 |
| InnovAge Holding (INNV) | United States | $1.470B | 0.00 |
| Omada Health (OMDA) | United States | $1.255B | 256.25 |
| Ryman Healthcare (RYHTY) | New Zealand | $1.241B | 0.00 |
| GoodRx Holdings (GDRX) | United States | $1.220B | 23.73 |
| Teladoc Health (TDOC) | United States | $1.181B | 0.00 |
| CryoPort (CYRX) | United States | $0.808B | 0.00 |
| GMR Solutions (GMRS) | United States | $0.716B | 0.00 |
| Enhabit (EHAB) | United States | $0.709B | 25.89 |
| Forward Industries (FWDI) | United States | $0.513B | 0.00 |
| Oncology Institute (TOI) | United States | $0.507B | 0.00 |
| Charming Medical (MCTA) | Hong Kong, SAR China | $0.504B | 0.00 |
| Strata Critical Medical (SRTA) | United States | $0.474B | 0.00 |
| SBC Medicals (SBC) | United States | $0.467B | 9.66 |
| Shoulder Innovations (SI) | United States | $0.382B | 0.00 |
| Auna S.A (AUNA) | Luxembourg | $0.377B | 5.47 |
| Embecta (EMBC) | United States | $0.297B | 2.57 |
| Biodesix (BDSX) | United States | $0.289B | 0.00 |
| So-Young (SY) | China | $0.266B | 0.00 |
| LifeMD (LFMD) | United States | $0.166B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.109B | 0.00 |
| Park Dental Partners (PARK) | United States | $0.101B | 0.00 |
| SkinHealth Systems (SKIN) | United States | $0.091B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.079B | 0.00 |
| QDM (QDMI) | Hong Kong, SAR China | $0.065B | 7.65 |
| Tevogen (TVGN) | United States | $0.049B | 0.00 |
| DocGo (DCGO) | United States | $0.037B | 0.00 |
| Lifeward (LFWD) | United States | $0.020B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.014B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.014B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.011B | 0.00 |
| Ainos (AIMD) | United States | $0.010B | 0.00 |
| XWELL (XWEL) | United States | $0.008B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.008B | 0.00 |
| Aclarion (ACON) | United States | $0.007B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.007B | 0.00 |
| 20/20 Biolabs (AIDX) | United States | $0.007B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.006B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.006B | 0.00 |
| Pomdoctor - (POM) | China | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.004B | 0.00 | |
| ISpecimen (ISPC) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.002B | 0.00 |
| Synergy CHC (SNYR) | United States | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |